NanoViricides announced that it has filed an Orphan Drug Application to the FDA for DengueCide, a drug candidate for the treatment of dengue and dengue hemorrhagic fever. DengueCide is a nanoviricide that has shown very high effectiveness in animal models of dengue virus infection and also in cell culture studies of dengue virus infection.
In the past 20 years, dengue fever has reemerged spreading to new geographic locations with increased epidemic activity, co-circulation of multiple serotypes, and the emergence of dengue hemorrhagic fever. This mosquito-borne disease is one of the most important tropical infectious diseases globally, with an estimated 400 million cases of dengue fever, over one million cases of dengue hemorrhagic fever, and 50,000-100,000 deaths annually. There is currently neither an effective drug treatment nor a vaccine for dengue virus infection. Tremendous efforts have been made for dengue vaccine development but, to date, no vaccine candidate has succeeded in clinical trials towards approval.
For more information call (203) 937-6137 or visit www.nanoviricides.com.